Periodic Reporting for period 1 - ScanZ (Point of care medical device enabling patient self-assessment for acne diagnosis support.)
Período documentado: 2015-02-01 hasta 2015-05-31
During the first medical trial at ORS Hospital Belgrade, mySkin obtained significant positive feedback from patients and medical professionals; and whilst scouting the dermatology clinics for holding medical trials during the PH2 project ScanZ has received strong interest from dermatology clinics across Europe as well as positive reviews from TechCrunch, CNET, NY Daily News, and the BBC.
The conducted (e/tele)-interviews with dermatologists have shown that there is a high demand for the ScanZ device. Prominent acne researchers have been looking or trying to develop such a device since 2005. Now that digital medical devices have become more recently available and popular, ScanZ is an ideal solution for implementation into their clinical staff and patient processes. The key criteria of selecting an appropriate device for the dermatologists was having a simple, easy to use device, that saves times, is affordable, and most importantly quantify acne and skin lesions.
Thanks to the Feasibility study, mySkin has decided to change the strategy by first focusing on the MD device, and then after understanding the clinical use-cases and patient flow, focus on the consumer edition (CE) of ScanZ. It would be the most efficient way to medicallyvalidate and certify the device and test both users experience and to become internationally recognized.
mySkin has achieved the business feasibility objectives defined in the PH1 proposal, by securing 4 hospitals (3 outside Serbia) for the clinical trials, obtaining interests of the EMDDA, conducting the comprehensive and market barriers analysis, as well as preparing the IP and marketing strategy and 5 years financial projection.